Aurobindo Pharma soars as its arm gets USFDA's nod to manufacture, market Dasatinib tablets

23 Apr 2025 Evaluate

Aurobindo Pharma is currently trading at Rs. 1240.40, up by 52.30 points or 4.40% from its previous closing of Rs. 1188.10 on the BSE.

The scrip opened at Rs. 1208.40 and has touched a high and low of Rs. 1244.95 and Rs. 1182.50 respectively. So far 69381 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1592.55 on 13-Sep-2024 and a 52 week low of Rs. 994.35 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 1244.95 and Rs. 1132.35 respectively. The current market cap of the company is Rs. 71894.53 crore.

The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 41.56% and 6.61% respectively.

Aurobindo Pharma’s wholly owned subsidiary -- Eugia Pharma Specialities has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Dasatinib tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, of Bristol-Myers Squibb Company (BMS). The product is expected to be launched in Q1FY26. 

The approved product has an estimated market size of $1.8 billion for the twelve months ending February 2025, according to IQVIA MAT. This is the 181st ANDA approval (including 9 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oncology oral and sterile specialty products. Dasatinib Tablets is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase; adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib; adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1212.65 -4.15 (-0.34%)
24-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1737.50
Dr. Reddys Lab 1266.35
Cipla 1496.35
Zydus Lifesciences 917.45
Lupin 2109.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×